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ABSTRACT
Objectives: Antibiotic resistance is one of the most persistent issues worldwide nowadays, and methicillin-resistant Staphylococcus aureus (MRSA) 
infection is one such issue where the standard therapeutic procedures involving powerful antibiotics have failed in controlling the infection.
Methods: In the present study, the antibacterial potency of the nonantibiotics troxipide (TR), mebeverine hydrochloride (Hcl), and their combinations 
with ceftriaxone (CEF) against MRSA has been investigated using microbiological assays of microplate dilution method and combination index 
interpretations of the nonantibiotics with β-lactam antibiotic CEF and the zone of inhibition method.
Results: The nonantibiotics ME and TR inhibited resistant strain tested in vitro in the checkerboard assay, where the results showed that CEF and 
TR exhibited minimum inhibitory concentration (MIC) at concentrations of 50 µg/ml and 318 µg/ml, respectively. Interestingly, CEF when combined 
with TR reduced the MIC to 8 µg/ml and 78 µg/ml. According to the results, CEF with TR exhibited synergistic interactions at the fractional inhibitory 
concentration of 0.36–1.4. ME and TR and its combinations, CEF with ME, and CEF with TR have considerable anti-MRSA efficacy, with synergism 
though at 36 h of incubation.
Conclusion: ME and TR being antispasmodic and antiulcer drugs can also be used against MRSA infections, which could prove to be favorable in the 
reduction of dosage of antibiotics such as CEF, and cutting down the need for additional administration of antibiotics to the patients affected with 
multiple complications such as gastrointestinal ulcer, spasm difficulties, and infection.
Keywords: Antibacterial activity, Ceftriaxone, Combination index interpretation, MebeverineHcl, Troxipide.
INTRODUCTION
Resistance to antibiotics occurs when an antibiotic loses its ability 
to kill or effectively controls the growth of bacteria. Every time, an 
antibiotic is taken the sensitive strains of bacteria gets killed and the 
resistant strain survives, which can rapidly multiply and cause serious 
infections. Inappropriate and prolonged use of antibiotics can actually 
accelerate the emergence of resistant bacterial strains [1]. The increase 
and spread of drug resistance over the past 50 years have led to the 
distribution of resistance genes among pathogenic microorganism [2]. 
Infections related to antibiotic resistance were initially observed 
in hospital settings among critically ill and immunocompromised 
patients. Recent studies show that these infections are reported to be 
increasing in public and certain instances, in live-stock animals [3,4], 
which makes it clear that infection is something which is contradictory 
to the good things in life: It is easy to get but hard to lose. Without 
effective treatment, the standard medical procedures will stand to 
fail or turn into high-risk procedures. According to the world health 
organization, antibiotic resistance in the pathogenic bacteria causing 
common infections is of high proportions (for instance, pneumonia, 
urinary tract infection, or blood infections) worldwide? Many bacterial 
infections caused by S. aureus, Klebsiella pneumoniae, Enterobacter 
cloacae, Escherichia coli, Enterococcus faecalis, etc., are treatable using 
antibiotics; however, with the development of resistance to multiple 
drugs of these bacterial strains, the general procedure of treatment has 
become complicated [5].
Under such circumstance, the exploration of alternative therapeutic 
agents that can fight against severe bacterial infections was crucial, and 
nonantibiotic agents that can confer antibacterial activity were brought 
into focus. Systematic searching from the mid-1960s, notably by many 
researchers gave real evidences of the fact that many eukaryotes-directed 
drugs antihistamine, antipsychotic, antihypertensive, antispasmodic, and 
anti-inflammatory have antimicrobial and antivirulence properties [6,7]. 
Such pharmaceutical compounds basically developed as drugs to treat 
noninfectious diseases which, on the other hand, have antimicrobial 
activities are called nonantibiotics [8]. In the present study, we have 
evaluated the antibacterial activity of antiulcer drug troxipide (TR) 
and antispasmodic drug mebeverine Hcl (ME) in vitro and discovered 
synergism with antibiotic ceftriaxone (CEF) against methicillin-
resistant Staphylococcus aureus (MRSA).
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i11.21535
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MATERIALS AND METHODS
Bacterial strains
Clinical strain Staphylococcus aureus was obtained from the KAP 
Viswanathan Medical College, Tiruchirappalli, Tamil Nadu, India. The 
MRSA strain was confirmed and stored at 4°C until use.
Drugs
CEF, TR, and ME were obtained as pure drug powders from Sigma 
Aldrich, India, and kept under refrigeration until use.
Media
Mueller-Hinton broth (MHB) and Mueller-Hinton agar (MHA) were 
prepared and steam sterilized at 15 psi for 15 min by autoclaving.
Preparation of inocula
The S. aureus was grown in MHB overnight at 37°C in an incubator 
under standard conditions. The harvested cells in the exponential 
phase culture were suspended in sterile distilled water and adjusted to 
a turbidity of 0.5 McFarland standard using a spectrophotometer (Cary-
60 UV-Visible, Agilent Technologies) at 600 nm.
Checkerboard methods for studying interaction between 
antibiotics and nonantibiotics
To determine the antibacterial efficacy between the individual and 
different combination of drugs, the following combinations, namely 
CEF+TR; CEF+ME and the clinical strain of MRSA have been studied 
in the following assay using the checkerboard method. Aliquots of log 
phase bacterial culture (turbidity of 0.5 McFarland standard) were 
transferred to microtiter plates containing tested concentrations of 
drugs as inferred from the minimum inhibitory concentration (MIC) 
assay [9,10]. The combination of different concentrations was used 
in the study. In the first row, only CEF and in the first column only TR 
or ME were distributed in microwell plates. CEF at 0.125–32 µg/ml; 
TR at 6.25–200 µg/ml; and ME at 1.56–100 µg/ml used individually. 
Whereas, in combination CEF + TR (1:10) – 0.25–8 µg/ml of CEF with 
2.5–80 µg/ml of TR, CEF + ME (1:10) – 0.25–8 µg/ml of CEF with 2.5–
80 µg/ml of ME. Dilute an overnight culture of MRSA in Mueller-Hinton 
broth to achieve optical density (OD) based inoculum of 1 × 105–5 × 105. 
Inoculate all wells (except the column specified which is considered 
as blank) with 50 µl of the diluted organism (the volume in each well 
should be 200 µl). The inoculated microtiter plates were incubated at 
37°C for 36 h. The growth inhibition was measured by determining 
the absorbance at 600 nm in a multimode microplate reader (Enspire, 
Perkin Elmer). From these readings, the synergistic and additive 
interactions were calculated [11-14].
The synergistic combination index (CI) was calculated in the 
isobologram software. The combination of the two test samples was 
graphically represented by dose-effect curve, CI value, dose-reduction 
index (DRI), and the isobole method which was interpreted in the 
isobologram software.
Dose effect was calculated from the following formula:
Absorbance of  positive control without drug  - 
Absorbance
( )
 of  test solution
Absorbance of  positive control
The percentage inhibition of each drug and its combination were 
obtained from dose-effect value multiplied by 100.
The CI value of the combined drugs CEF, TR, and CEF+TR was calculated 
using the formula
CI = MIC of  substance A in combination
MIC of  substance A alone
MIC of  substance B in combination
MIC of  substance B 
   +
alone
In the above equation substance A in the numerator denotes MIC of 
CEF in CEF+TR combination, and in denominator substance A alone 
indicates MIC of CEF alone; similarly, in numerator substance B means 
MIC of TR in combination of CEF+TR, and in denominator substance B 
alone means MIC of TR alone.
The goodness of fit to the straight line can be determined by the linear 
correlation coefficient (r value) calculated from x and y intercepts 
which represent
y=ax+b, A plot x=log (D) Vs y=log (fa/fu), where D – Dose of the 
drug; fa – fraction affected (bacterial growth inhibition); fu – fraction 
unaffected(no growth inhibition).
fa+fu=1, fu=1-fa.
DRI was calculated from the following equation, where (DA)1 is the 
dose of drug CEF alone that inhibits x%, D is the dose of the drug in 
combination. DRI can be really obtained from the reciprocal of each 
term of the CI equation, thus
(DRI)1=(DA)1/(D)1; (DRI)2=(DB)2/(D)2
DRI >1 and <1 indicates favorable and not favorable dose reduction, 
respectively; DRI=1 indicates no dose reduction.
Determination of antibacterial efficacy of nonantibiotics ME and 
TR, and its combinations with CEF by zone of inhibition method
The combination of CEF+TR and CEF+ME was tested by studying the 
zone of inhibition by using the well-diffusion technique. Plates were 
prepared using preinoculated (1-day-old cultures of 0.5 McFarland 
standard turbidity) MHA, on the surface of which four wells were 
prepared using gel puncture and filled with different concentrations of 
test agents and its combinations with respect to the MIC values. The 
plates were incubated at 37°C for 18 h, and the zone of inhibition of 
MRSA was measured. The experiments were performed in triplicates, 
and the synergistic effects were statistically evaluated [12].
RESULTS
Synergistic effect observed between CEF, TR, and CEF+TR 
combination against MRSA
The bacterial growth inhibitory effect of CEF, TR, and CEF+TR on MRSA 
was observed and interpreted. The CI values of the combined drugs CEF, 
TR, and CEF+TR were calculated using the above-said formula and its 
results summarized in Table 1. It shows the results of the checkerboard 
assay for the determination of MIC of the antibiotics CEF and TR and 
its combination of CEF+TR against the clinical strain of MRSA. CEF 
and TR exhibited MIC at a concentration of 50 µg/ml and 318 µg/ml, 
respectively. Whereas, CEF+TR as a combination has shown a significant 
reduction in the required effective concentration of CEF and TR which is 
8 µg/ml and 78 µg/ml, respectively. This shows that CEF and TR exhibit 
a synergistic effect when put together as a combination (CEF+TR), 
thereby exhibiting increased in the antibacterial potency against MRSA. 
The CI values of the combined drugs were calculated. According to the 
results, synergistic interactions were derived for CEF+TR (0.36–1.4).
From the above-said formula, growth affected (fa) and growth 
unaffected (fu) were calculated, and the dose-effect curve was plotted 
using the isobologram software. Graphical representation of a dose-
effect curve, a logarithmic CI, a DRI , and isobologram for each test 
sample and its combination have been presented below in Fig. 1a-d. The 
dose-effect curve was plotted using optical density (OD) value in Fig. 1a, 
with the help of the curve x intercept, y intercept, and the median effect 
of the dose was calculated. Logarithmic CI plot for CEF+TR indicated 
in Fig. 1b, where CI point lying between the diagonal line indicates 
synergistic effects and DRI of the combination shown in Fig. 1c, DRI>1 
indicates a favorable dose reduction.
Isobologram used to interpret 50%, 75%, and 90% inhibition is shown 
in Fig. 1d. Results revealed in the CEF+TR combination, data point 
136
Asian J Pharm Clin Res, Vol 11, Issue 11, 2018, 134-138
 Akilandeswari and Ruckmani 
(values) on the isobologram, where lower left indicates synergistic 
effect. From the above observations, the MIC of CEF showed sensitivity 
at certain concentrations; whereas, its effect was enhanced even in low 
concentrations when the drug was used in combination.
Synergistic effect observed between CEF, ME and CEF+ME 
combination against MRSA
The bacterial growth inhibitory effect of CEF, ME, and CEF+ME on MRSA 
was observed and interpreted. The CI values of the combined drugs 
CEF, ME, and CEF+ME were calculated using the above-mentioned 
formula and its results represented in Table 2. It shows the results of 
the checkerboard assay for the determination of MIC of the antibiotics 
CEF and ME and its combination CEF+ME against the clinical strain of 
MRSA. CEF and ME exhibited MIC at the concentration of 50 µg/ml and 
80 µg/ml, respectively. Whereas, CEF+ME as a combination has shown 
a slight increased reduction in the required effective concentration 
of CEF and ME which is 10.59 µg/ml and 78 µg/ml, respectively. This 
shows that CEF and ME exhibits a lesser synergistic effect when put 
together as a combination (CEF+ME), thereby exhibiting only a slight 
increase in the antibacterial potency against MRSA. The CI value of 
the combined drugs was calculated, and it is not under the CI value 
below 1.5. According to the results, lesser synergistic interactions were 
derived for CEF + ME (1.0–1.67).
Graphical representation of a dose-effect curve, logarithmic CI, DRI, 
and isobologram for each test sample and its combination has been 
presented in Fig. 2a-d. The dose-effect curve was plotted using the OD 
value in Fig. 2a, with the help of the curve x intercept, y intercept, and 
the median effect of the dose was calculated. Logarithmic CI plot for 
CEF+ME shown in Fig. 2b, where CI point lying on the diagonal line 
indicates synergistic effects and DRI of the combination represented 
in Fig. 2c, DRI <1 indicates nearly favorable dose reduction. 
Isobolograms for 50%, 75%, and 90% inhibition are shown in Fig. 2d. 
Combination data point on the lower left indicates synergism. In the 
present combination of CEF+ME, IC75, and IC50 showed the nearly less 
synergistic effect.
Synergistic effect confirmed in zone of inhibition method
In Table 3, the disc diffusion tests demonstrated the inhibitory effects 
of CEF, TR, and ME individually inhibited the bacterial growth 25.3 mm, 
16 mm, and 16mm, respectively; whereas, CEF+TR and CEF+ME against 
MRSA show an inhibitory zone of 43 mm and 41 mm, respectively. Thus, 
the synergistic effects of CEF+TR and CEF+ME combined drugs were 
observed to some extent.
DISCUSSION
Identification of mecA gene in clinical sample of S. aureus has been 
confirmed in earlier literature [13]. The presence of mecA gene in the 
clinical sample confirmed the MRSA strain through which it is made sure 
that the working strain is MRSA. TR, 3-(3,4,5-trimethoxy benzamide) 
piperidine, is used in the treatment of gastroesophageal reflux disease 
and ME, 4-[ethyl-[1-(4-methoxy phenyl) propan-2-yl]amino]butyl 
3,4-dimethoxy benzoate hydrochloride, is used in the management 
of irritable bowel syndrome and abdominal cramping. Results from 
checkerboard assay for the determination of MIC of the antibiotics 
CEF, ME, and TR and its combinations AM + ME, CEF + ME, and CEF + 
TR against the clinical strain of MRSA show that the test agents under 
combination exhibit a visible synergistic effect. Based on the results, CEF 
+ TR as a combination shows a significant 1/6th and 1/5th reduction in 
the required effective concentration of CEF and TR with CI ranging from 
0.36 to 1.4, whereas, CEF+ME as a combination shows 1/5th reduction 
in the required effective concentration of CEF; however, there is a visible 
similarity in the required effective concentration of ME with CI ranging 
from 1.0 to 1.6 collectively. The major aim for achieving synergy in drug 
combination is that it allows dose-reduction for the good therapeutic 
effect. The beneficial significance of dose reduction is the reduced 
toxicity toward the host. DRI (DRI) denotes how many fold of dose 
reduction is allowed for each drug due to synergism when compared 
with the dose of each drug alone. From the above investigation, it is 
inferred that the combination of antibiotics and nonantibiotics CEF+TR 
having CI>0.5 has a synergistic effect as any combination having CI <0.5 
only is considered to have strong synergistic effect. Unlike the above 
combinations, as CEF + ME shows less decrease in the MIC of ME, 
the combination is considered as favorable even though at very low-
dose reduction. Although CEF+TR combination projects a synergistic 
effect, the combination does exhibit MRSA growth inhibition; hence, 
this combination of drugs can be further studied with different 
concentrations for strong and improved anti-MRSA activity.
Disc-diffusion test has confirmed the inhibitory effects of CEF, TR, and 
ME individually with bacterial growth inhibited up to 25.3 mm, 16 mm, 
and 16 mm, respectively; whereas, CEF+TR and CEF+ME show an 
inhibitory zone of 43 mm and 41 mm, respectively. Therefore, the visible 
synergistic effect of combined drugs could be observed to some extent 
with better antimicrobial efficacy compared to that of individual test 
samples. However, both TR and ME growth inhibitions were achieved 
after 36 h, where the duration of action is longer when compared with 
that of the conventional antibiotics (18 h).
Table 1: Checkerboard method for non-antibiotics CEF, TR, and CEF+TR
Test agents (µg/ml Growth inhibition 50% Growth inhibition 75% Growth inhibition 90%
CI value Conc.µg/ml CI value Conc. µg/ml CI value Conc. µg/ml
CEF - 1.04 - - 7.19 - - 49.76 -
TR - - 78.05 - - 171.87 - - 318.61
CEF+TR 1.45 1.33 13.27 0.63 3.22 32.18 0.36 7.8 78.02
All the values represent triplicate values. CI <1 indicates synergism, CI >1 indicates additive effect; CI <0.5, synergy; CI 0.5–0.75 partial synergy. CEF and TR exhibited 
MIC at 49.8, 318.6, respectively, when CEF combines with TR the dose reduced to 1/6 of the MIC of CEF (7.8 µg/ml) and 1/5 of the MIC of TR (78 µg/ml) respectively. 
CEF: Ceftriaxone, TR: Troxipide, CEF+TR: Ceftriaxone with troxipide, ME: MebeverineHcl, CI: Combination index, MIC: Minimum inhibitory concentration
Table 2: Checkerboard method for nonantibiotics CEF, ME, and CEF+ME
Test agents (µg/ml Growth inhibition 50% Growth inhibition 75% Growth inhibition 90%
CI value Conc. µg/ml CI value Conc.µg/ml CI value Conc. µg/ml
CEF - 1.04 - - 7.19 - - 49.76 -
ME - - 28.99 - - 48.08 - - 79.76
CEF+ME 1.67 1.28 12.8 1.28 3.68 36.82 1.54 10.59 78.94
All the values represent triplicate values. CI <1 indicates synergism, CI >1 indicates additive effect, CI <0.5, synergy; CI 0.5–0.75, partial synergy. CEF and ME individually 
exhibited MIC at 50, 80 µg/ml, respectively, when it was combined with ME dose reduced to 1/5 of the MIC of CEF whereas ME dose same as that of MIC of ME. 
CI: Combination index, CEF: Ceftriaxone, ME: MebeverineHcl, MIC: Minimum inhibitory concentration
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From the discussion, it can be concluded that both the proposed 
nonantibiotics ME and TR that are commercially marketed as 
antispasmodic and antiulcer drugs have noticeable antibacterial efficacy. 
The fact that the chemical structure of ME, 3-(3,4,5-trimethobenzamide) 
piperidine side chain, and TR, 3-(3,4,5-trimethoxy benzamide) 
piperidine attributes to the antibacterial activity [15].
It has been proved from the earlier studies that antibiotics with 
nonantibiotics when used in combination had an enhanced 
antibacterial capability against Gram-positive and Gram-negative 
microorganisms [16]. On the basis of MIC and disc-diffusion method, 
the antibacterial activity of ME and TR and its following synergistic 
effect with an antibiotic CEF is similar to the nonantibiotics 
Fig. 1: CI determination for CEF with TR against MRSA. (a) Dose-effect curve for CEF, TR, and CEF+TR. (b) Logarithmic combination index plot 
for CEF, TR, and CEF+TR. Log (CI): Logarithmic combination index. (c) Logarithmic dose-reduction index plot for combination CEF+TR [1:10]. 
(d) Isobologram for combination CEF+TR [1:10]. Fa: Fraction affected (growth inhibited), CEF: Ceftriaxone, TR: Troxipide, CEFTR: Ceftriaxone with 
troxipide, Log (DRI): Logarithmic dose reduction index, CI: Combination index, Fa=0.75 indicates 75% inhibition, Fa=0.9 indicates 90% inhibition, 
Dose A indicates ceftriaxone, Dose B indicates troxipide, Fa=0.5 indicates 50% inhibition, MRSA: Methicillin resistant Staphylococcus aureus
a b
c d
Fig. 2: CI determination for CEF with ME against MRSA. (a) Dose-effect curve for CEF, ME, and CEF+ME. (b) Logarithmic combination index 
plot for CEF, ME, and CEF+ME. (c) Log (DRI) plot for combo: CEFME (CEF+ME [1:10]). (d) Isobologram for Combo: CEFME (CEF+ME [1:10]). Fa: 
Fraction affected (growth inhibited), CEF: Ceftriaxone, TR: Troxipide, CEFTR: Ceftriaxone with troxipide. Log (CI): Logarithmic combination 
index, CEFME: Ceftriaxone with mebeverine hydrochloride, Log (DRI): Logarithmic dose reduction index, ME: Mebeverine hydrochloride, 
Dose A indicates ceftriaxone, Dose B indicated MebeverineHcl, Fa=0.5 indicates 50% inhibition, Fa=0.75 indicates 75% inhibition, Fa=0.9 
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diclofenac sodium [17] oxyfedrine [12] omeprazole, ranitidine [18], 
dicyclomine [15], azelastin [19], and synthetic derivatives [20,21]. 
Although the mechanism of bacterial inhibition of nonantibiotics was 
not well known, it could be due to multiple factors interfering with 
bacterial cell wall synthesis. Specifically, multiple receptors found in 
the MRSA strain could be responsible for the reduction [22]. These 
ligands might prove to be moderate inhibitors for MRSA infections, thus 
proving to be potentially beneficial for creating a novel antibacterial 
therapeutic molecule, and the compounds ME and TR were found to 
have antibacterial activity.
CONCLUSION
The study it is concluded that the nonantibiotics ME and TR and 
its combinations, with β-lactam antibiotics, CEF+TR have potency 
against MRSA infection, which could be a synergistic impact of the 
combinations. These combinations of drugs can be further studied 
with different concentrations for strong and improved anti-MRSA 
activity. ME and TR being antispasmodic and antiulcer drugs can also 
be used against MRSA infections which could prove to be favorable in 
the reduction of dosage of antibiotics such as CEF, and cutting down the 
need for additional administration of antibiotics to the patients affected 
with multiple complications such as gastrointestinal ulcer, spasm 
difficulties, and infection.
ACKNOWLEDGMENTS
The authors gratefully acknowledge the financial grant awarded 
by the Department of Science and Technology, Ministry of Science 
and Technology, Government of India, in the form of facility project 
“National facility for Drug Development for Academia, Pharmaceutical 
and Allied industries.”
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Levy SB. The Antibiotic Paradox: How the Misuse of Antibiotics 
Destroys their Curative Powers. 2nd ed. Cambridge, MA: Perseus 
Publishing, Cambridge; 2002. p. 353.
2. Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, 
Pagès JM, et al. Potential role of non-antibiotics (helper compounds) 
in the treatment of multidrug-resistant gram-negative infections: 
Mechanisms for their direct and indirect activities. Int J Antimicrob 
Agents 2008;31:198-208.
3. Alanis AJ. Resistance to antibiotics: Are we in the post-antibiotic era? 
Arch Med Res 2005;36:697-705.
4. Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, 
et al. Meticillin-resistant Staphylococcus aureus (MRSA): Global 
epidemiology and harmonisation of typing methods. Int J Antimicrob 
Agents 2012;39:273-82.
5. Christine L. Case. Discover a New Antibiotic; 1998.
6. Dutta NK, Annadurai S, Mazumdar K, Dastidar SG, Kristiansen JE, 
Molnar J, et al. Potential management of resistant microbial infections 
with a novel non-antibiotic: The anti-inflammatory drug diclofenac 
sodium. Int J Antimicrob Agents 2007;30:242-9.
7. Mazumdar K, Dastidar SG, Park JH, Dutta NK. The anti-inflammatory 
non-antibiotic helper compound diclofenac: An antibacterial drug 
target. Eur J Clin Microbiol Infect Dis 2009;28:881-91.
8. Kristiansen JE. Antimicrobial activity of non-antibiotics. ASM News 
1991;57:135-9.
9. Busri A, Puspitawati R, Utami S. Antibacterial effect of java turmeric 
ethanol extract against dual-species Streptococcus mutans and 
Streptococcus sanguinis biofilm (in vitro). Asian J Pharm Clin Res 
2017;10:57-60.
10. Sukandar EY, Kurniati NF, Wikaningtyas P, Agprikani D. Antibacterial 
interaction of combination of ethanolic extract of Zingiber officinale 
var Rubrum rhizome, Boesenbergia pandurata rhizome and Stevia 
rebaudiana leaves with certain antibiotics against infectious mouth 
microbial. Asian J Pharm Clin Res 2016;9:332-5.
11. Kumar KA, Ganguly K, Mazumdar K, Dutta NK, Dastidar SG, 
Chakrabarty AN, et al. Amlodipine: A cardiovascular drug with 
powerful antimicrobial property. Acta Microbiol Pol 2003;52:285-92.
12. Mazumdar K, Ganguly K, Kumar KA, Dutta NK, Chakrabarty AN, 
Dastidar SG, et al. Antimicrobial potentiality of a new non-antibiotic: 
The cardiovascular drug oxyfedrine hydrochloride. Microbiol Res 
2003;158:259-64.
13. Eumkeb G, Chukrathok S. Synergistic activity and mechanism of action 
of ceftazidime and apigenin combination against ceftazidime-resistant 
Enterobacter cloacae. Phytomedicine 2013;20:262-9.
14. Devi KP, Nisha SA, Sakthivel R, Pandian SK. Eugenol (an essential 
oil of clove) acts as an antibacterial agent against salmonella typhi by 
disrupting the cellular membrane. J Ethnopharmacol 2010;130:107-15.
15. Karak P, Kumar KA, Mazumdar K, Mookerjee M, Dastidar SG. 
Antibacterial potential of an antispasmodic drug dicyclomine 
hydrochloride. Indian J Med Res 2003;118:192-6.
16. Akilandeswari K, Ruckmani K. Antibacterial potentiality of anti-ulcer 
and anti-spasmodic drugs with selected antibiotics against methicillin-
resistant Staphylococcus aureus - In vitro and in silico studies. 
Bangladesh J Pharmacol 2015;10:875-83.
17. Dutta NK, Mazumdar K, Seok SH, Park JH. The anti-inflammatory 
drug diclofenac retains anti-listerial activity in vivo. Lett Appl Microbiol 
2008;47:106-11.
18. Alkuraishy HM. In vitro antibacterial effects of selective histaminic 
receptor Type 2 blockers: A novel study. Webmed Cent Pharmacol 
2011;2:WMC002636.
19. El-Nakeeb MA, Abou-Shleib HM, Khalil AM, Omar HG, 
El-Halfawy OM. Reversal of antibiotic resistance in gram-positive 
bacteria by the antihistaminic azelastine. APMIS 2012;120:215-20.
20. Shafiq B, Muhi-Eldeen Z, Al-kaissi E, Al-adham IS. Synthesis, 
structural elucidation and antimicrobial evaluation of 2-{4-(tamino)-2-
(but-2-yn-1-yl)}-1, 3 benzothiazole derivatives. Int J Pharm PharmSci 
2016;8:189-93.
21. Dilipkumar P, Vipul S, Desh DP, Roopesh KM. Synthesis, 
characterization and antimicrobial evaluation of some 1, 2, 4- triazole 
derivatives. Int J Pharm Pharm Sci 2014;6:213-6.
22. Tomasz AS, Tomasz A. Role of penicillin-binding protein 2 (PBP2) in 
the antibiotic susceptibility and cell wall cross-linking of Staphylococcus 
aureus: Evidence for the cooperative functioning of PBP2, PBP4, and 
PBP2A. J Bacteriol 2005;5:1815-24.
Table 3: Determination of the synergistic effect of the 
combination of CEF+TR and CEF+ME against MRSA by the zone 
of inhibition method
S. No Name of the selected drug 
combinations µg/10 µl
Zone of inhibition in mm 
against MRSA
1 CEF (50) 25.3±0.58
2 TR (300) 16±1.0
3 ME (75) 16±1.5
4 CEF+TR (8+80) 43±0.58
5 CEF+ME (11+80) 41±1.58
±indicates standard deviation of triplicates values. CEF: Ceftriaxone, 
TR: Troxipide, CEF+TR: Ceftriaxone with troxipide, MRSA: Methicillin-resistant 
Staphylococcus aureus, ME: MebeverineHcl
